Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q1 2023 Earnings Presentation
14 slides from Hansa Biopharma Ab's earnings presentation, Apr 20, 2023
Slide 1: Conference Call Presentation
Conference Call Presentation Interim report January – March 2023 Lund, April 20, 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Q1 progress on key deliverables
Q1 progress on key deliverables Our mission is to become a global leader in rare diseases 1 European launch of Idefirix® progresses as planned 2 Exciting pipeline advances 3 Performance continues at pace ü Repeat business of Idefirix® at first ü Guillain-Barré Syndrome (GBS): ü Total Q1 revenue - SE
Slide 4: Market Access secured in the five largest markets in Europe
Market Access secured in the five largest markets in Europe representing 15,000 annual kidney transplants Market access has now been secured in 12 European countries and procedures are ongoing in eight countries including Portugal, Belgium and Switzerland Health Technology Assessments 3,649 (HTA) do
Slide 5: Exciting pipeline advances potential new medicines in areas of high unmet need
Exciting pipeline advances potential new medicines in areas of high unmet need Antibody Mediated Guillain-Barré Rejection (AMR) Syndrome (GBS) Anti-GBM U.S. ConfIdeS Phase 2 Phase 2 Phase 3 Phase 3 • 30/30 patients enrolled • 30/30 patients enrolled • Open-label, randomised • 62/64 patients enrolled
Slide 6: Imlifidase facilitates transduction of AAV8 in a mouse model
Imlifidase facilitates transduction of AAV8 in a mouse model Imlifidase treatment neutralises the inhibitory effect of IgG and facilitates AAV8 transduction in target cells TT1362_qPCR_liver_mean_grp 2_3 TT1362_qPCR_heart_mean_grp In TT1362_LUC_mean_grp severe combined immunodeficient 2_3 (SCID) mic
Slide 7: Broad clinical pipeline in transplantation and autoimmune diseases
Broad clinical pipeline in transplantation and autoimmune diseases Candidate/ Research/ Marketing Project Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements around EU: Kidney transplantation in highly sensitized patients1,2 *) *
Slide 8: Q1 2023 Revenue amounted to SEK 24m including SEK 14m in product sales
Q1 2023 Revenue amounted to SEK 24m including SEK 14m in product sales Revenue (Q/Q) Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 67,1 22.7 30,3 30,8 SEKm 26,4 24,2 43.7 Product sales 24.2 20.3 19.5 14.3 Revenue recognition from 5.2 6.2 9.2 9.0 AskBio and Sarepta 0.8 0.8 0.7 1.3 0.9 Axis-Shield Revenue (12M/12M) 2
Slide 9: Continued investments in our commercialization and R&D activities
Continued investments in our commercialization and R&D activities SG&A expenses (Q/Q) R&D expenses (Q/Q) Net loss (Q/Q) Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 -80 -138 -154 -149 -90 -83 -84 -170 -103 -205 SEKm SEKm SEKm -71 -93 -90 -92 -93 SG&A expe
Slide 10: With current cash position and projected burn-rate, Hansa's operations are financed into 2025
With current cash position and projected burn-rate, Hansa’s operations are financed into 2025 Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) Number of employees (Q/Q) Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 -131 -136 -129 -110 -207 1,496 Employees SEKm SEKm 1,287 1,215 754 616 159 Operating cas
Slide 11: Key near term milestones
Key near term milestones ✓ Sarepta DMD U.S. Kidney U.S. Kidney pre-treatment: AMR Phase 2: transplantation: U.S. Kidney GBS Phase 2: transplantation: Commence Full data Complete transplantation Complete enrollment Complete enrollment Clinical study readout randomization BLA submission (H1 2023) (H1
Slide 12: Q&A
Q&A Visit our new web site www.hansabiopharma.com … at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives… 12
Slide 13: Contact our Investor Relations and Corporate Affairs team
Contact our Investor Relations and Corporate Affairs team Contact Calendar and events Klaus Sindahl April 20, 2023 Redeye Investor Forum, Gothenburg April 21 2023 Redeye Lunch presentation, Stockholm VP, Head of Investor Relations April 25 2023 Kempen Life Sciences Conference 2023, Amsterdam Mobile:
Slide 14: HANSAT
MZ HANSAT BIOPHARMA